MX6A Panoramica delle azioni Grand Pharmaceutical Group Limited, una holding di investimento, si occupa di ricerca e sviluppo, produzione e vendita di preparati farmaceutici e dispositivi medici, prodotti biotecnologici e sanitari e materie prime farmaceutiche. Maggiori dettagli
Premi Analisi del rischio Vedi tutti gli assegni di rischio Catturate i vostri pensieri, i link e la narrativa aziendale
Grand Pharmaceutical Group Limited Concorrenti Storia dei prezzi e prestazioni
Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Grand Pharmaceutical Group Prezzi storici delle azioni Prezzo attuale dell'azione HK$0.56 Massimo di 52 settimane HK$0.62 Minimo di 52 settimane HK$0.38 Beta 0.71 Variazione di 1 mese 7.77% Variazione a 3 mesi 9.90% Variazione di 1 anno 30.28% Variazione a 3 anni -17.16% Variazione a 5 anni n/a Variazione dall'IPO -21.61%
Notizie e aggiornamenti recenti
Grand Pharmaceutical Group Limited Submits New Drug Application for the Global Innovative Product GPN01768 to the National Medical Products Administration of the People's Republic of China Dec 16
Grand Pharmaceutical Group Limited's Global Innovative Intravascular Dual-Mode Imaging System NovasyNC Receives Registration Certificate for Medical Device by National Medical Products Administration of the People's Republic of China Dec 12
Telix Pharmaceuticals Limited and Grand Pharmaceutical Group Limited Announces First Patient Dosed in Phase III ZIRCON-CP Trial of TLX250-CDx for Kidney Cancer Imaging in Chinese Patients Nov 28
Grand Pharmaceutical Group Limited and Nanjing Kainite Medical Technology Company Limited Announce First Adjustable Intracranial Stent Retriever Product Produce in China Approve for Commercialization by NMPA Oct 22
National Medical Products Administration Accepts Grand Pharmaceutical Group Limited's Phase III Clinical Study Application of ITM-11 Oct 14
First half 2024 earnings released: EPS: HK$0.44 (vs HK$0.29 in 1H 2023) Sep 27 Vedi altri aggiornamenti
Grand Pharmaceutical Group Limited Submits New Drug Application for the Global Innovative Product GPN01768 to the National Medical Products Administration of the People's Republic of China Dec 16
Grand Pharmaceutical Group Limited's Global Innovative Intravascular Dual-Mode Imaging System NovasyNC Receives Registration Certificate for Medical Device by National Medical Products Administration of the People's Republic of China Dec 12
Telix Pharmaceuticals Limited and Grand Pharmaceutical Group Limited Announces First Patient Dosed in Phase III ZIRCON-CP Trial of TLX250-CDx for Kidney Cancer Imaging in Chinese Patients Nov 28
Grand Pharmaceutical Group Limited and Nanjing Kainite Medical Technology Company Limited Announce First Adjustable Intracranial Stent Retriever Product Produce in China Approve for Commercialization by NMPA Oct 22
National Medical Products Administration Accepts Grand Pharmaceutical Group Limited's Phase III Clinical Study Application of ITM-11 Oct 14
First half 2024 earnings released: EPS: HK$0.44 (vs HK$0.29 in 1H 2023) Sep 27
New minor risk - Share price stability Sep 19
Grand Pharmaceutical Group Limited Appoints Lam Chit Yee Jessica as Executive Director Aug 27
First half 2024 earnings released: EPS: HK$0.44 (vs HK$0.29 in 1H 2023) Aug 22
Grand Pharmaceutical Group Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2024 Aug 15
Grand Pharmaceutical Group Limited to Report First Half, 2024 Results on Aug 19, 2024 Aug 09
Grand Pharmaceutical Group Limited Announces Executive Changes Jun 24
Grand Pharmaceutical Group Limited Announces the Phase I Clinical Study Conducted in China of the Groups Global Innovative Ophthalmic Drug Gpn00884 Has Completed the First Patient Enrollment Jun 13
Grand Pharmaceutical Group Limited Approves Final Dividend for the Year Ended 31 December 2023 Jun 05
Upcoming dividend of HK$0.26 per share May 30
Grand Pharmaceutical Group Limited, Annual General Meeting, Jun 04, 2024 Apr 29
Grand Pharmaceutical Group Limited, Annual General Meeting, Jun 04, 2024 Apr 28
Executive Chairman recently bought €44k worth of stock Apr 26
Dividend of HK$0.26 announced Mar 25 Grand Pharmaceutical Group Limited Proposes Ordinary Final Cash Dividend for the Year Ended 31 December 2023, Payable on 27 June 2024 Mar 21
Full year 2023 earnings released: EPS: HK$0.54 (vs HK$0.59 in FY 2022) Mar 20
Grand Pharmaceutical Group Limited to Report Fiscal Year 2023 Results on Mar 19, 2024 Mar 08
Grand Pharmaceutical Group Limited Announces Update on Global Innovative Ophthalmic Drug GPN00884 Mar 07
Less than half of directors are independent Feb 07
Grand Pharmaceutical Group Limited Announces the Investigational New Drug Application in China of the Group's Global Innovative Ophthalmic Drug GPN00884 Was Accepted by NMPA Dec 27
Less than half of directors are independent Dec 16
Grand Pharmaceutical Group Limited Announces the Investigational New Drug Application of ARC01 (A002) Nov 03
Grand Pharmaceutical Group Limited Announces Phase III Clinical Trial in China of the Groups Global Innovative Ophthalmic Drug GPN00833 Has Completed the First Patient Enrollment and Dosing Oct 25
Grand Pharmaceutical Group Limited Announces Phase III Clinical Study in China of the Group's Global Innovation Drug RYaltris® Compound Nasal Spray Has Completed and Successfully Met Primary Endpoint Sep 14
Grand Pharmaceutical Group Limited Announces That the Phase I Clinical Trial of Apad, A Global Innovative Drug Independently Developed by the Group for the Treatment of Sepsis, Has Completed First Subject Enrollment and Dosing Approved Recently Aug 18
First half 2023 earnings released: EPS: HK$0.29 (vs HK$0.20 in 1H 2022) Aug 13
Grand Pharmaceutical Group Limited Announces New Mra Drug of the Group Eplerenone Tablets Was Granted Drug Registration Certificate Aug 04
Grand Pharmaceutical Group Limited to Report First Half, 2023 Results on Aug 10, 2023 Aug 01
Grand Pharmaceutical Group Limited Announces Approval by National Medical Products Administration to Conduct Phase II Clinical Study in China Jul 18
Less than half of directors are independent Jul 12
Grand Pharmaceutical Group Limited Appoints Yang Guang as an Executive Director Jul 01
Grand Pharmaceutical Group Limited Announces Resignation of Niu Zhanqi as Executive Director Jun 22
Less than half of directors are independent Jun 08 Grand Pharmaceutical Group Limited Announces Board Changes
Upcoming dividend of HK$0.14 per share at 2.8% yield Jun 02
Less than half of directors are independent May 18 Grand Pharmaceutical Group Limited Announces the Multicenter Phase III Clinical Trial of Ryaltris Compound Nasal Spray
Full year 2022 earnings released: EPS: HK$0.59 (vs HK$0.68 in FY 2021) Mar 23 National Medical Products Administration of the People's Republic of China Accepts Grand Pharmaceutical Group Limited's Investigational New Drug Applications of the Group Three Innovative Products in China
Grand Pharmaceutical Group Limited Conducts Clinical Trials of its Innovative Oral Small Molecule 3Cl Protease Inhibitor GS221 Against COVID-19 Dec 29
Less than half of directors are independent Nov 16
Grand Pharmaceutical Group Limited Announces NMPA Approves Clinical Trial Application in China for Global Innovative Radionuclide-Drug Conjugate TLX591-CDx Oct 18
First half 2022 earnings released: EPS: HK$0.20 (vs HK$0.34 in 1H 2021) Sep 29
Grand Pharmaceutical Group Limited Announces Clinical Trial Application in China for Global Innovative Radionuclide-Drug Conjugate TLX250-CDX Approved by NMPA Sep 29
Less than half of directors are independent Aug 23
First half 2022 earnings released Aug 11
Grand Pharmaceutical Group Limited Provides Unaudited Earnings Guidance for Six Months Ended 30 June 2022 Aug 06
Grand Pharmaceutical Group Announces Clinical Trial Applications in China for Global Innovative Radionuclide-Drug Conjugates TLX591-CDX AND TLX250-CDX Accepted by NMPA Aug 02
Grand Pharmaceutical Group Limited to Report First Half, 2022 Results on Aug 10, 2022 Jul 30
Less than half of directors are independent Jul 07
Executive Director recently bought €64k worth of stock Jun 10
Grand Pharmaceutical Group Limited Declares Final Dividend for the Year Ended 31 December 2021 May 28
Less than half of directors are independent May 02
Grand Pharmaceutical Group Limited Announces Phase III Clinical Trial of Global Innovative Drug Ryaltris Compound Nasal Spray Successfully Completed the First Patient Enrollment in China Apr 08
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 18
Now 21% undervalued after recent price drop Feb 23
Sirtex Medical and Grand Pharmaceutical Group Limited Receive NDA Approval of SIR-Spheres® Y-90 Resin Microspheres in China from the National Medical Products Administration Feb 10
First half 2021 earnings released: EPS HK$0.34 (vs HK$0.21 in 1H 2020) Sep 25
First half 2021 earnings released: EPS HK$0.34 (vs HK$0.21 in 1H 2020) Aug 12
China Grand Pharmaceutical and Healthcare Holdings Limited (SEHK:512) agreed to acquire 22.2% interest in CoRISMA MCS Systems, Inc for $12 million. Aug 08
Less than half of directors are independent Jul 27 Rendimenti per gli azionisti MX6A DE Pharmaceuticals DE Mercato 7D 6.7% -0.2% -1.3% 1Y 30.3% -16.2% 14.9%
Vedi i rendimenti completi degli azionisti
Ritorno vs Industria: MX6A ha superato il German Pharmaceuticals che ha restituito -16.2 % nell'ultimo anno.
Rendimento vs Mercato: MX6A ha superato il mercato German che ha restituito 14.9 % nell'ultimo anno.
Volatilità dei prezzi Is MX6A's price volatile compared to industry and market? MX6A volatility MX6A Average Weekly Movement 8.6% Pharmaceuticals Industry Average Movement 4.1% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.6% 10% least volatile stocks in DE Market 2.5%
Prezzo delle azioni stabile: Negli ultimi 3 mesi il prezzo delle azioni di MX6A è stato volatile rispetto al mercato German.
Volatilità nel tempo: La volatilità settimanale ( 9% ) di MX6A è rimasta stabile nell'ultimo anno, ma è comunque superiore al 75% delle azioni German.
Informazioni sull'azienda Grand Pharmaceutical Group Limited, una holding di investimento, si occupa di ricerca e sviluppo, produzione e vendita di preparati farmaceutici e dispositivi medici, prodotti biotecnologici e sanitari e materie prime farmaceutiche. L'azienda offre prodotti per l'apparato respiratorio, l'oftalmologia, le emergenze cerebro-cardiovascolari e le biotecnologie. L'azienda produce e vende prodotti farmaceutici, taurina, prodotti agrochimici, farmaci chimici e aminoacidi.
Mostra di più Grand Pharmaceutical Group Limited Riepilogo dei fondamenti Come si confrontano gli utili e i ricavi di Grand Pharmaceutical Group con la sua capitalizzazione di mercato? MX6A statistiche fondamentali Capitalizzazione di mercato €2.03b Guadagni(TTM ) €294.93m Ricavi(TTM ) €1.30b
Guadagni e ricavi Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM) MX6A Conto economico (TTM ) Ricavi HK$10.59b Costo del fatturato HK$4.34b Profitto lordo HK$6.25b Altre spese HK$3.84b Guadagni HK$2.41b
Ultimi guadagni dichiarati
Jun 30, 2024
Prossima data di guadagno
n/a
Utile per azione (EPS) 0.69 Margine lordo 59.00% Margine di profitto netto 22.75% Rapporto debito/patrimonio netto 28.1%
Come si è comportato MX6A nel lungo periodo?
Vedi performance storica e confronto Dividendi
5.5% Rendimento attuale del dividendo
38% Rapporto di remunerazione
Analisi aziendale e situazione dei dati finanziari Dati Ultimo aggiornamento (ora UTC) Analisi dell'azienda 2025/02/20 16:25 Prezzo dell'azione a fine giornata 2025/02/20 00:00 Guadagni 2024/06/30 Guadagni annuali 2023/12/31
Fonti dei dati I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC . I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
Pacchetto Dati Tempistica Esempio Fonte USA * Dati finanziari della società 10 anni Conto economico Rendiconto finanziario Bilancio Stime di consenso degli analisti +3 anni Previsioni finanziarie Obiettivi di prezzo degli analisti Prezzi di mercato 30 anni Prezzi delle azioni Dividendi, scissioni e azioni Proprietà 10 anni Top azionisti Insider trading Gestione 10 anni Team di leadership Consiglio di amministrazione Sviluppi principali 10 anni
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più .
Modello di analisi e Snowflake I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github ; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube .
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github .
Fonti analitiche Grand Pharmaceutical Group Limited è coperta da 7 analisti. 4 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
Analista Istituzione Yanyin Zhu China International Capital Corporation Limited Xiao Wei Lin Everbright Securities Co. Ltd. Yiling Chen Guosen Securities Co., Ltd.
Mostra 4 altri analisti 